Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic mel...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

Danzzzzzzzz Jul. 2 at 3:51 PM

$BMY $LLY $NVS $PNT $RYZB

0 · Reply

JuggernautRaider Jul. 2 at 9:37 AM

$TNXP am I reading this right? Did Tonix’s general counsel just get a MILLION SHARES JUST TO BE THEIR LAWYER? I was annoyed at first. Then I became Mad. now… I AM F***iNG FURIOUS AS A LARGE TNXP SHAREHOLDER! @alphaonetrading where are you! @Proposition_Joe - WHERE ARE YOU! My neighbor MISTER COOPER… we need to go to 200 CONNELL TOMORROW! I AM CLEARING MY GOT DAMN AFTERNOON! I want to have A MAN TO MAN CHAT WITH DOCTOR LEDERMAN… now!!! ⏰ Tick tock doc.. time is up, and you are OUT! ⚾️ God DAMN SETH! F him! I AM LEADING THE REVOLT! FIRE LEDERMAN! We want MARK ALLES!! 🧠 he is a free agent, he sold CELG and Turning Point to $BMY .,. And he is a Marine 🇺🇸 I am working people. Rich Bagger knows Mark. Seth’s days as Tonix’s CEO have a finite date. 🗳️ Get off your ass and VOTE! ~ Genius Health Care Academy, LLC - right here from New Jersey 💪 💊 🚀

1 · Reply

Johnny_Lever Jul. 2 at 12:58 AM

$BMY More pull back.

0 · Reply

Mike22332233 Jul. 1 at 11:03 PM

$SLS UPDATED ... I said the following one month ago when SLS was $8-$9 about it going to $18-$22 after 80th event ... and people laughed ... I don't hear from them anymore !!! ... Timeline/Price Prediction: ... SLS will jump to $18-$22 after 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results 2 weeks later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a possible 5 way Bidding War -- between $MRK, $ABBV, $BMY, $PFE, and RHHBY -- the FINAL BO PRICE will be reached at $202 in Q4 of 2026 !!! ... LIKE & FOLLOW me 👉 @Mike22332233 for SLS insight you will find nowhere else

3 · Reply

Mike22332233 Jul. 1 at 6:35 PM

$SLS DID YOU SEE MY STUNNING PREDICTION ... If the REGAL GPS trial comes in with my estimated HR of 0.27-0.33 (or lower), which would be AMAZINGLY GAME CHANGING ... We will get BO bids (and a bidding war) FROM EACH OF THE FOLLOWING: $MRK $BMY $PFE $ABBV RHHBY That's correct ... ALL 5 OF THEM!!! ... Like if you agree & FOLLOW ME @Mike22332233 for BO price

1 · Reply

JuggernautRaider Jul. 1 at 6:10 PM

$BMY 👍 💪 💊

0 · Reply

Jwa68 Jul. 1 at 1:10 PM

$GANX $COYA Our day is coming with both names. I'm virtually certain of it. Sooner rather than later. In my mind DRL buys Coya, outside chance $BMY. Gain could be anyone of a handful including Bristol Myers, and so many others. Patent cliff is approaching, pipelines are empty, neurodegenerative diseases is a rappidly growing sweet spot.

0 · Reply

SellasgpsCurativeBAT11 Jul. 1 at 11:18 AM

$ABBV $BMY $PFE $SLS Expecting major Positive PR/Filing within next 24 hours. Biggest Catalyst PR in Sellas Corporate history. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jul. 1 at 3:35 AM

$ABBV $BMY $PFE $SLS # 4 BMS: BMS faces also a patent cliff exposure: Eliquis loses US exclusivity in April 2028, Opdivo (nivolumab) follows around 2028–2029. These two drugs together represent a dominant share of BMS revenue. The urgency is real for them and comparable to Merck's. GPS + nivolumab combinations have already been studied in mesothelioma and ovarian cancer through investigator-sponsored MSK trials where BMS provided nivolumab, giving them existing scientific readthrough. BMS's strategic rationale is similar to Merck's: GPS extends nivolumab's clinical lifecycle through combination data generating new indications post-biosimilar entry. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jul. 1 at 3:33 AM

$ABBV $BMY $PFE $SLS # 3 The Keytruda patent expiration 2028 is existential as it generated $31.7B in 2025, which is 49% of Merck's total $65B revenue and core US patent expiry in 2028 and biosimilars from Celltrion, Samsung Bioepis, and Amgen already in preparation. They have a target of $70B+ revenue by the mid-2030s, which requires replacing a significant portion of Keytruda's revenue within a decade. GPS could solve this in a specific way: GPS + pembrolizumab combination data across 20 WT1-expressing cancer types would generate new label updates, new clinical indications, and extended physician mind-share for Keytruda as a combination backbone. This would be lifecycle management at plattorm scale, not only revenue addition. ✌️🙏❤️‍🩹

0 · Reply

Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb

BMY INTC PGR

Jun 18, 2026, 6:59 AM EDT - 16 days ago

Market Cap	118.71B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	9.52
Forward PE	8.93
Profit Margin	14.64%
Debt to Equity Ratio	2.21

Volume	10,003,900
Avg Vol	12,050,512
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	85%
Beta	0.23
Analysts	Sell
Price Target	$62.81